Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Inclusion Criteria:

* Histologically confirmed and immunophenotypically (CD20)-positive lymphoma at original diagnosis, progression, or relapse
* Refractory to conventional therapy

  * First recurrent/refractory CD20-positive non-Hodgkin's lymphoma (NHL) allowed if ineligible for or refused regimens with known curative potential (high-dose chemotherapy plus bone marrow transplantation) (if available)
  * Second or third progression and/or recurrence of NHL
  * Second or third relapse/refractory CD20-positive Hodgkin's lymphoma
  * CD20-positive, post-transplantation lymphoproliferative lymphoma that is medically refractory (decreased immunosuppression) to rituximab and/or chemotherapy
  * Medically refractory, HIV-associated, CD20-positive NHL
  * Recurrent/refractory CD20-positive lymphoblastic lymphoma
* Autologous peripheral blood stem cells (PBSC) collected, selected for a minimum of 2 x 10\^6 CD34-positive cells per kg, and cryopreserved before study entry
* Meets one of the following criteria for bone marrow reserve:

  * Good marrow reserve, defined by both of the following:

    * No prior myeloablative stem cell transplantation (SCT)
    * No prior extensive radiotherapy, defined by any of the following:

      * Prior total body irradiation
      * Prior radiotherapy dose of 3,600 cGy or more to cranio-spinal axis
      * Prior radiotherapy to 50% or more of bone marrow
  * Poor marrow reserve, defined by either or both of the following:

    * Prior myeloablative SCT
    * Prior extensive radiotherapy
* Performance status - Lansky 50-100% (age 10 and under)
* Performance status - Karnofsky 50-100% (age 11 to 21)
* At least 2 months
* Absolute neutrophil count ≥ 1,000/mm\^3
* Platelet count ≥ 100,000/mm\^3 for patients with poor marrow reserve (transfusion independent)
* Platelet count ≥ 150,000 for patients with good marrow reserve (transfusion independent)
* Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
* Bilirubin ≤ 1.5 times upper limit of normal (ULN)
* ALT ≤ 5 times ULN
* Albumin ≥ 2 g/dL
* Creatinine normal
* Creatinine clearance or glomerular filtration rate ≥ 70 mL/min
* Shortening fraction ≥ 27% by echocardiogram
* Ejection fraction ≥ 50% by MUGA
* No dyspnea at rest
* No exercise intolerance
* Oxygen saturation (SpO\_2) \> 94% by pulse oximetry (if there is a clinical indication for SpO\_2 assessment)
* Not pregnant or nursing
* Negative pregnancy test
* No documented infection that is unresponsive to appropriate antibiotic, antiviral, or antifungal therapy
* No grade 2 or greater CNS toxicity
* Seizure disorder allowed if well controlled and on anticonvulsants
* See Disease Characteristics
* Recovered from prior immunotherapy
* At least 1 week since prior antineoplastic biologic agents
* Prior SCT allowed if the following criteria are met:

  * At least 60 days since prior SCT
  * Full hematopoietic reconstitution post-SCT
* No evidence of active acute or chronic graft-versus-host disease if post- allogeneic SCT
* No concurrent sargramostim (GM-CSF)
* See Disease Characteristics
* At least 3 weeks since prior myelosuppressive chemotherapy (4 weeks for nitrosourea) and recovered
* See Disease Characteristics
* Recovered from prior radiotherapy
* No concurrent medications that would interact with the study drug